Intralytix, Inc.
http://www.intralytix.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Intralytix, Inc.
Ferring Looks For Early Microbiome Wins, But Willing To Do Heavy Lifting
Switzerland’s Ferring is diving deep into the microbiome, looking at a range of potential therapy platforms including bacteriophage and probiotics. Its CSO believes a microbiome-based therapeutic approach could benefit dermatological and women’s health conditions, as well as gastro-intestinal disorders.
Hard-Core Computing To Drive Microbiome-based R&D
Israel’s RondinX is analyzing the microbiome with specific algorithms in order to develop new therapeutic approaches to disease.
Ferring To Pioneer Phage Therapies For Crohn’s Disease
The Switzerland-based company targets a novel therapeutic area still small enough for it to make a difference, the development of bacteriophage therapies for disorders thought to be associated with abnormal bacterial microflora, with proof-of-principle studies to begin later this year.
Phico Therapeutics Ltd.
Phico is developing bacteriophage to deliver antibacterial-based drugs for treating antibiotic-resistant and other bacterial infections. But unlike others using bacteriophage themselves to attack bacteria, Phico's technology employs bacteriophage as the vehicle for delivering a protein that shuts down bacterial activity.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Nutraceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice